North America Genomic Testing Market Zooming 2.6X to Reach USD 27.45 Billion by 2032

Published | 27 February 2026

North America Genomic Testing Market is rapidly evolving because of growing evidence of genomics utility across oncology (tumor profiling, MRD), rare disease diagnosis, pharmacogenomics, and prenatal & infectious disease testing, and clinicians increasingly adopting genomics to improve diagnosis, and treatment selection & outcomes.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated North America Genomic Testing Market size by value at USD 10.56 billion in 2025. During the forecast period between 2026 and 2032, BlueWeave expects North America Genomic Testing Market size to boom at a significant CAGR of 14.62% reaching a value of USD 27.45 billion by 2032. Prominent growth drivers of North America Genomic Testing Market include the clinical expansion and unmet needs, rapid development and approval of targeted therapies, and immunotherapies require companion and comprehensive genomic tests to identify eligible patients, creating tight linkage between drug launches and diagnostic volumes.

Opportunity – Growing Clinical Adoption and Expanding Indications

Growing clinical adoption of genomic testing and expanding indications reflect a shift from niche, specialty use toward mainstream clinical practice across multiple areas of medicine. It is expected to boost the growth of North America Genomic Testing Market in the coming years. As evidence accumulates that genomic data can improve diagnosis, guide targeted therapies, predict drug response, and inform preventive care, clinicians increasingly order tests for oncology (tumor profiling, minimal residual disease monitoring), rare and undiagnosed diseases, pharmacogenomics, prenatal screening, and infectious disease surveillance. This broader clinical uptake is driven by more affordable and faster sequencing technologies, clearer guideline recommendations for certain indications, and tighter links between diagnostics and approved targeted treatments.

Sample Request: https://www.blueweaveconsulting.com/report/north-america-genomic-testing-market/report-sample

Oncology Application Leads North America Genomic Testing Market

Oncology currently dominates North America Genomic Testing Market by application, driven by strong clinical demand, therapeutic innovation, and clear reimbursement pathways. Tumor profiling, including targeted gene panels, comprehensive genomic profiling (CGP), and liquid biopsy assays for circulating tumor DNA, accounts for the largest market share, as precision oncology links test results directly to approved targeted therapies, clinical trial enrollment, and treatment decisions; this creates immediate, high-value use cases that payers and providers prioritize. Additionally, routine testing for biomarkers, for instance, EGFR, ALK, BRCA, MSI, PD-L1-associated genomics, across common cancers, rising adoption of minimal residual disease (MRD) monitoring, and growth in tumor-agnostic indications, including NTRK fusions and MSI-high, further expand volumes.

Impact of Escalating Geopolitical Tensions on North America Genomic Testing Market

Escalating geopolitical tensions, including trade restrictions, export controls on sequencing technologies and reagents, cross-border data governance clashes, and strained international collaborations, could affect the growth of North America Genomic Testing Market by constraining supply chains, raising costs, and fragmenting research networks. Restrictions on the import or export of key equipment, consumables, and cloud computing services may cause reagent shortages, longer lead times for instruments, and greater reliance on more expensive domestic or alternative suppliers, squeezing lab margins and slowing test turnaround. Heightened scrutiny over data sharing and differing national rules on genomic data localization or access can inhibit multinational research partnerships and slow the aggregation of diverse reference datasets, which are critical for accurate variant interpretation and equitable test performance.

Hospitals & Health Systems Dominate North America Genomic Testing Market

The hospitals & health systems segment holds the largest market share of North America Genomic Testing Market by end user, as they combine high patient volumes, integrated clinical services, and growing in‑house genomic capabilities that drive demand for both diagnostic and monitoring tests. Large academic medical centers and tertiary hospitals host specialized programs, such as oncology centers, neonatal & pediatric intensive care units, and rare‑disease clinics, that routinely order sequencing for tumor profiling, rapid neonatal whole‑exome/genome diagnostics, and complex germline testing. These institutions also invest in on‑site laboratories or preferred partnerships to control turnaround times, integrate genomic results into EHRs and clinical decision support, and support multidisciplinary tumor boards and precision medicine programs.

Competitive Landscape

Major players operating in North America Genomic Testing Market include Illumina, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Quest Diagnostics, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies, Inc., Myriad Genetics, Inc., Genomic Health, Inc., 23andMe, Inc., Foundation Medicine, Inc., Color Genomics, Inc., Amgen, Inc., and 24 Genetics. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Don’t miss the business opportunity of North America Genomic Testing Market. Consult our analysts to gain crucial insights and facilitate your business growth.

The report's in-depth analysis provides information about growth potential, upcoming trends, and North America Genomic Testing Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in North America Genomic Testing Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Scope of the Report

About Us

BlueWeave Consulting provides all-inclusive Market Intelligence (MI) Solutions to businesses regarding various products and services online & offline. We offer comprehensive market research reports by analyzing qualitative and quantitative data to boost your business solution's performance. BlueWeave Consulting has built its reputation from scratch by delivering quality inputs and nourishing long-lasting relationships with its clients. We are a promising digital MI solutions company providing agile assistance to make your business endeavors successful.

Contact Us:

BlueWeave Consulting & Research Pvt Ltd

+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662

info@blueweaveconsulting.com